Noteworthy

Jun 25, 2010
Pharmaceutical Executive
Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters—and how they plan to lead the industry through the turbulent times ahead.
Jun 17, 2010
Pharmaceutical Executive
A new "upstream" healthcare model may help deliver on the longstanding promise of personalized medicine.
May 11, 2010
Pharmaceutical Executive
Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.
Apr 27, 2010
Pharmaceutical Executive
As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO.
Apr 13, 2010
Pharmaceutical Executive
The faces and names behind the year's best pharmaceutical advertising.
Apr 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Re-examining service provider roles can bring safety and speed on the road to registration.
Mar 01, 2010
Pharmaceutical Executive
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?
Mar 01, 2010
Pharmaceutical Executive
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
Feb 01, 2010
Pharmaceutical Executive
Sales compensation practices are due for an overhaul in 2010.
Feb 01, 2010
Pharmaceutical Executive
The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?
native1_300x100
lorem ipsum